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in community isolates from North India:
frequency and predisposing factorsExtended-spectrum beta-lactamases (ESBL) constitute a
growing class of b-lactamases that are infiltrating our hospi-
tals. They are often plasmid-mediated and are frequently
expressed by different Enterobacteriaceae. They often
remain undetected by current isolation and susceptibility
methods.1
Recently a number of reports have documented the emer-
gence of ESBL in the community in long-term care facilities
and ambulatory patients with chronic conditions. These
reservoirs may feed back into the pool of ESBL in the hospital
environment.2 Our retrospective analysis was carried out to
describe the prevalence of ESBL-producing organisms
amongst our isolates and the proportion that were from
community or non-hospitalized patients. We also describe
the prevalence of factors that predispose to ESBL production
in these patients.
The study was conducted in the Department of Microbiol-
ogy, Government Medical College and Hospital, Chandigarh,
between January and October, 2004. Three hundred unique
Enterobacteriaceae isolated from clinical samples were
tested for ESBL production. Antimicrobial susceptibility test-
ing was performed by the disk diffusion method according to
NCCLS guidelines.3 ESBL screening was by disk diffusion4 and
confirmation by the double disk synergy test (DDST).5
We reviewed the medical records of patients with com-
munity onset infection with ESBL producers, for demography,
co-morbidity, and history of previous antimicrobial therapy
and prior hospitalization. Community onset infections were
defined as individuals who did not have a history of hospita-
lization in the preceding three months and who were either
outpatients or admitted patients who had had their first
positive culture results from samples obtained within 48 h
of hospital admission. Other hospitalized patients and those
hospitalized within three months were deemed to have
nosocomial infections.6
Out of the 300 bacterial strains, 72 (24%) were ESBL
producers. Fifty of these 72 were from patients who met
the criteria of community onset infection. Among these, 44
were Escherichia coli and six were Klebsiella pneumoniae.
The total numbers of E. coli and K. pneumoniae isolated
during the study period from the community-associated
infection cases were 184 and 30, respectively. Clinical sam-
ples from which these ESBL strains were isolated included
urine (36), pus (10), and sputum (4). On reviewing the
medical records of the 50 patients with ESBL strains from
community onset infection the following percentages of
predisposing factors were found: 50% (25) of the patients
were>60 years of age, 74% (37) were male patients, 76% (38)
had a history of previous use of second or third generation
cephalosporins, 74% (37) had a history of previous use of
quinolones, and 48% (24) had a history of hospitalization prior
to the immediate past three months. Only 24% (12) of the
patients had a history of diabetes mellitus (DM) and only 12%
(6) of the patients had K. pneumoniae infection.
A study carried out by Mathur et al. reported the rate of
ESBL producers to be 68% and another by Tankhiwale et al.
found it to be 48%.7,8 This variation may be real and be due tostudy design.
A high rate of resistance to various antibiotics was seen in
our study (amikacin 24%, gentamicin 75%, ciprofloxacin 65%,
ceftazidime 88%, cefotaxime 90%, ceftriaxone 87%, cefepime
62%, amoxicillin/clavulanic acid 69%) although all the ESBL
producers were susceptible to imipenem and piperacillin/
tazobactam. Other workers have also reported high rates of
antimicrobial resistance among ESBL producers.7 These high
rates could be because of poorly directed therapy and over-
the-counter sales.
Factors predisposing to ESBL production, as reported by
Colodner et al.,9 were common in our study: age over sixty
years, male sex, prior history of taking antibiotics, and
hospitalization. In addition to these factors, Rodriguez Bano
et al. reported DM and recurrent urinary tract infection (UTI)
as risk factors for ESBL production.6 In our study 12 of 50
community patients with ESBL producers had associated DM.
Pitout et al. studied ESBL in E. coli from community onset
infections and found females to be commonly infected.10 In
our study most ESBL-producing E. coli were from males. This
could be explained on the basis that elderly male patients are
prone to drug resistant strains because of prior antibiotic
therapy and hospitalization. However, study design differ-
ences are just as likely. Ours is not a study of community-
acquired UTI, where most infections are treated empirically,
but is based on samples sent to the hospital laboratory.
The population studied may therefore be biased by medical
and social factors that affect a sample being submitted. Our
study does, however, show the high prevalence of ESBL in
ambulatory patients who had not been admitted in the near
past. We found DDST to be an easy, cheap, sensitive and
easily reproducible test.
Our results show that the non-hospitalized community
that submits samples for analysis, from which many are
hospital outpatients, has become infiltrated with ESBL
enzymes. Although this is a self-selecting group, heightened
vigilance and further studies regarding dissemination of ESBL
in the community should be undertaken.
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doi:10.1016/j.ijid.2006.02.002Hemophagocytosis and pulmonary involvement
in brucellosis
We report the case of a 45-year-old woman who presented
with fever, hepatosplenomegaly, jaundice, rash, and tachyp-
nea. Wright’s serum agglutination and 2-mercaptoethanol (2-
ME) tests were both positive in the range of 1/2560 and
hemophagocytosis was shown in bone marrow aspiration.
The illness began with flu-like symptoms 15 days earlier.
Four days before admission she had developed jaundice,
headache, myalgia, malaise, anorexia, nausea, and a pro-
ductive cough. There was no history of previous disease. Her
occupation involved all aspects of animal husbandry includ-
ing the slaughter and skinning of animals. On physical exam-
ination, icteric sclera, blood clots in the pharyngeal pouch,
ecchymosis (Figure 1), and tenderness in the right upper
quadrant were found. Her platelet count at the time of
admission was 13  109 cells/L. Twenty-four hours after
admission she developed epistaxis. Oral ribavirin was started
with a probable diagnosis of Crimean-Congo hemorrhagic
fever.
On the second hospital day, laboratory findings were as
follows: hemoglobin (Hb) 11.2 g/dL, LDH 2345 IU/L, alkaline
phosphatase 391 IU/L, SGOT 277 IU/L (N <13—39), and SGPT
322 IU/L (N <27—40). Her white blood cell (WBC) count was5.6  109 cells/L, erythrocyte sedimentation rate was 8 mm/
h, direct bilirubin 15.4 mg/dL, total bilirubin 22.1 mg/dL,
Wright’s agglutination test 1/2560, and 2-ME was 1/2560.
Owing to positive Wright’s agglutination and 2-ME tests,
ribavirin was changed to doxycycline plus gentamicin.
Four days after admission laboratory tests revealed pan-
cytopenia: platelet count 12  109 cells/L, Hb 8.5 g/dL, and
WBC 3.5  109 cells/L. Bone marrow aspiration revealed an
increase in histiocytic lineage and phagocytosis of nucleated
red blood cells and platelets (hemophagocytosis). The cul-
tures of bone marrow were negative. Other laboratory tests
revealed negative blood cultures and serum ferritin
>1000 ng/mL.
Five days after admission, high resolution computed
tomography of the chest was performed due to persistent
tachypnea and rales, and showed consolidation in both lungs.
After three days of treatment with hydrocortisone (200 mg/
day) and anti-brucellar drugs, the platelet count increased,
liver enzymes decreased (SGPT 130 IU/L, SGOT 91 IU/L), and
prothrombin time (PT) and partial thromboplastin time (PTT)
returned to normal.
Mild hematologic abnormalities are common in brucellosis
and usually subside with treatment of the disease itself.
Thrombocytopenia may be severe and associated with pur-
pura and bleeding. Steroids have been recommended in
severe thrombocytopenia associated with human brucello-
sis.1 Severe disorders such as hemophagocytic syndromes
have also been described.2 Hemophagocytic syndrome is
associated with a broad spectrum of diseases such as viral,
bacterial and mycobacterial diseases.3 Signs and symptoms
of hemophagocytic syndromes are often similar to common
infections or mimic fever of unknown origin or hepatitis.
Fever, splenomegaly, and hepatomegaly are the most com-
mon clinical findings and lymphadenopathy, jaundice, and
rashes can also be found. Hemophagocytic syndrome may
result in pulmonary involvement.4
In daily practice, the diagnosis of brucellosis is established
by a positiveWright’s agglutination test in a titer of1/160 in
association with an appropriate clinical setting.5 The bru-
cella infection in our patient was established with strongly
positive serology (standard tube agglutination (STA) test).
